{"acne": 4.48, "blindness": 2.03, "blood creatine phosphokinase increased": 6.3, "blood lactate dehydrogenase increased": 4.17, "brain neoplasm": 9.44, "brain oedema": 2.3, "c-reactive protein increased": 3.94, "cardiomyopathy": 2.77, "cardiotoxicity": 4.3, "central nervous system lesion": 10.85, "cholestasis": 4.75, "concomitant disease aggravated": 2.81, "death": 5.14, "dehydration": 2.53, "dermatitis acneiform": 24.46, "disease progression": 3.07, "disseminated intravascular coagulation": 2.1, "drug resistance": 2.32, "dry skin": 3.62, "dysphagia": 2.13, "ejection fraction decreased": 21.74, "electrolyte imbalance": 2.42, "encephalitis": 2.09, "erythema nodosum": 17.32, "general physical health deterioration": 2.47, "haemophagocytic lymphohistiocytosis": 9.7, "hepatic cytolysis": 5.67, "hepatic enzyme increased": 2.06, "hepatitis": 2.03, "hospitalisation": 2.61, "hyperkeratosis": 5.8, "hyperpyrexia": 2.34, "hyperthermia": 4.34, "intestinal perforation": 3.64, "lipase increased": 3.33, "liver disorder": 2.5, "liver function test increased": 4.15, "lung adenocarcinoma": 14.43, "lung neoplasm maligt": 3.01, "lymphocyte count decreased": 3.17, "lymphoedema": 3.18, "maligt melanoma": 66.47, "maligt melanoma stage iii": 63.63, "maligt melanoma stage iv": 213.74, "maligt neoplasm progression": 20.29, "melanoma recurrent": 134.25, "metastases to bone": 9.74, "metastases to central nervous system": 76.25, "metastases to liver": 9.61, "metastases to lung": 16.35, "metastases to lymph nodes": 19.14, "metastases to meninges": 25.31, "metastases to peritoneum": 10.4, "metastases to skin": 35.02, "metastasis": 21.82, "metastatic maligt melanoma": 200.83, "neoplasm": 4.96, "non-small cell lung cancer": 45.45, "panniculitis": 42.66, "papilloedema": 3.9, "paronychia": 6.64, "pneumonitis": 3.36, "product storage error": 2.43, "product use in unapproved indication": 6.97, "pulmonary mass": 2.94, "pyrexia": 2.69, "rash maculo-papular": 2.16, "rash pustular": 3.04, "recurrent cancer": 11.6, "retinal detachment": 12.13, "retinopathy": 5.1, "rhabdomyolysis": 5.03, "sarcoidosis": 6.06, "second primary maligcy": 12.99, "serous retinal detachment": 33.9, "skin lesion": 2.91, "skin toxicity": 7.82, "soft tissue sarcoma": 37.33, "therapy partial responder": 3.03, "uveitis": 24.58, "visual impairment": 3.01, "vitreous floaters": 2.78}